Diversified Trust Co Sells 6,221 Shares of Stryker Corporation $SYK

Key Points

• Diversified Trust Co reduced its stake in Stryker Corporation by 42.1%, bringing its ownership to 8,546 shares valued at $3,381,000 as of the last reporting period.
• Multiple analysts are optimistic about Stryker, with 14 buying ratings and a consensus target price of $430.33, reflecting confidence in the company's performance.
• Stryker recently announced a quarterly dividend of $0.84 per share, with a 0.9% yield, highlighting the company’s commitment to returning value to shareholders.

Diversified Trust Co cut its stake in Stryker Corporation (NYSE:SYK - Free Report) by 42.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,546 shares of the medical technology company's stock after selling 6,221 shares during the period. Diversified Trust Co's holdings in Stryker were worth $3,381,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. Vise Technologies Inc. boosted its stake in shares of Stryker by 100.2% during the fourth quarter. Vise Technologies Inc. now owns 3,620 shares of the medical technology company's stock valued at $1,303,000 after purchasing an additional 1,812 shares during the period. Parr Mcknight Wealth Management Group LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $1,532,000. Pinney & Scofield Inc. bought a new position in shares of Stryker during the 4th quarter worth $130,000. Finally, Wilson & Boucher Capital Management LLC increased its position in Stryker by 0.6% during the 4th quarter. Wilson & Boucher Capital Management LLC now owns 8,820 shares of the medical technology company's stock valued at $3,176,000 after buying an additional 50 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on SYK shares. Needham & Company LLC raised their price target on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Wells Fargo & Company increased their price objective on Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Evercore ISI upped their target price on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Finally, Rothschild & Co Redburn started coverage on shares of Stryker in a research note on Thursday. They issued a "neutral" rating and a $420.00 target price on the stock. Fourteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Stryker has an average rating of "Moderate Buy" and an average target price of $430.33.

Stryker Trading Down 0.3%

NYSE:SYK traded down $1.23 during trading hours on Friday, hitting $376.61. The company had a trading volume of 1,924,253 shares, compared to its average volume of 985,669. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The stock has a 50-day moving average price of $387.52 and a 200 day moving average price of $379.05. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company has a market capitalization of $143.98 billion, a PE ratio of 49.88, a price-to-earnings-growth ratio of 2.71 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the previous year, the business earned $2.81 EPS. The company's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.